What is B. Riley’s Estimate for biote FY2024 Earnings?

biote Corp. (NASDAQ:BTMD) – Equities research analysts at B. Riley boosted their FY2024 EPS estimates for shares of biote in a research report issued to clients and investors on Wednesday, November 13th. B. Riley analyst J. Van. Sinderen now expects that the company will post earnings of $0.74 per share for the year, up from their prior estimate of $0.50. The consensus estimate for biote’s current full-year earnings is $0.53 per share. B. Riley also issued estimates for biote’s Q4 2024 earnings at $0.06 EPS, FY2025 earnings at $0.47 EPS and FY2026 earnings at $0.70 EPS.

biote Price Performance

biote stock opened at $6.57 on Friday. biote has a one year low of $3.65 and a one year high of $8.44. The firm has a market capitalization of $356.23 million, a P/E ratio of 25.27 and a beta of 0.94. The business has a fifty day moving average price of $5.53 and a 200-day moving average price of $6.28.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BTMD. Dimensional Fund Advisors LP lifted its position in biote by 1,016.6% during the second quarter. Dimensional Fund Advisors LP now owns 660,069 shares of the company’s stock valued at $4,931,000 after purchasing an additional 600,956 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of biote by 251.8% during the 2nd quarter. Renaissance Technologies LLC now owns 193,077 shares of the company’s stock valued at $1,442,000 after buying an additional 138,200 shares in the last quarter. Wasatch Advisors LP lifted its holdings in shares of biote by 8.4% during the 3rd quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company’s stock worth $7,772,000 after acquiring an additional 107,792 shares during the last quarter. Sanders Morris Harris LLC lifted its holdings in shares of biote by 131.2% during the 3rd quarter. Sanders Morris Harris LLC now owns 180,965 shares of the company’s stock worth $1,010,000 after acquiring an additional 102,706 shares during the last quarter. Finally, GDS Wealth Management purchased a new position in biote in the second quarter worth $432,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.